A Medtronic official said today on LinkedIn that the company won CE mark for its Crescent RA jugular dual lumen catheter.
Giuseppe Savoja, the medtech giant’s senior business director for Western Europe, posted the announcement on LinkedIn:
“Exciting times! I’m proud and thrilled to announce that the Medtronic Crescent RA jugular dual lumen catheter is now finally CE-marked!”
The Crescent RA jugular dual lumen catheter offers a right atrial design. It includes both an introducer for percutaneous technique and a blunt-tip obturator for a surgical cut-down technique. The technology provides both venous drainage and reinfusion of blood via the jugular vein.
Medtronic designed the catheter with radiopaque markers to identify drainage sites, reinfusion port, catheter tip and axial orientation. Its crescent-shaped lumen and large reinfusion port help optimize pressure flow performance. Multiple suture points also provide stability, the company says. This reduces the chance of twisting or migration when the patient moves.
Crescent RA has an indication for use in pediatric patients with acute respiratory failure requiring veno-venous extracorporeal membrane oxygenation where other available treatment options have failed and continued clinical deterioration is expected or the risk of death is imminent.
Savoja wrote that, with CE mark, Medtronic can now offer groundbreaking technology that can positively impact the lives of babies, children and their families.
At Medtronic, innovation drives our mission to transform lives and make healthcare accessible to those in need,” he wrote. “This milestone represents a significant step forward in providing essential therapy to our most vulnerable patients. The CE mark of Crescent RA is an important milestone within our exciting journey dedicated to extracorporeal life support. This achievement highlights our unwavering commitment to advancing healthcare innovations and improving the quality of life for patients, families and communities.
